Cabergoline Treatment in Invasive Giant Prolactinoma [PDF]
Patients with invasive giant prolactinoma suffer from a constellation of symptoms including headache, blurred vision, lethargy, and sexual dysfunction. Cabergoline, a potent dopamine agonist, is a known medication prescribed for the treatment of invasive
Mussa Almalki
exaly +10 more sources
Beat the giant: case of a giant prolactinoma during pregnancy on cabergoline [PDF]
Giant prolactinomas are a rare entity; during pregnancy, the risk for complications associated with these tumors is higher. Here, we report a case of a young woman who had an invasive, giant prolactinoma post resection with residual disease who became ...
Wael M Almistehi, Mussa H Almalki
doaj +7 more sources
Surgical Management of Giant Prolactinomas: A Descriptive Study [PDF]
Introduction. Giant prolactinoma (GP) is a rare pituitary lactotropic cell tumor larger than 4 cm in its widest dimension, and is less likely than a smaller prolactinoma to achieve prolactin normalization on dopamine agonist (DA) monotherapy.
Michelle D. Lundholm +5 more
doaj +5 more sources
A case of giant prolactinoma and pituitary hemorrhage with the late recovery of pituitary function: A case report [PDF]
Hypogonadotropic hypogonadism is a common finding in patients who are diagnosed with a prolactinoma. It can be accompanied by the presence of other pituitary hormone deficits, including secondary adrenal insufficiency and central hypothyroidism.
Lakshmi P Menon, Dinesh Edem
doaj +3 more sources
Aggressive giant prolactinoma: a case report [PDF]
Background Managing treatment-resistant aggressive giant prolactinoma can be challenging, as the diagnosis is often complex, and treatment beyond dopamine agonists, surgery, and radiotherapy is limited.
Marisa Khatijah Borhan +1 more
doaj +4 more sources
Giant prolactinoma with progressive cranial settling and central herniation: a case report [PDF]
Background Giant prolactinoma (size > 4 cm) is a rare condition and accounts for less than 1% of pituitary adenomas. In even rarer cases, these lesions may involve craniocervical structures requiring surgical intervention. The present case is the largest
Taha Shahbazi +3 more
doaj +3 more sources
Status epilepticus induced by treatment with dopamine agonist therapy for giant prolactinoma: a case report [PDF]
Background Dopamine agonists are the standard first-line medical therapy for prolactinoma. We report a rare case of giant prolactinoma with a first epileptic seizure due to rapid reduction of the tumor as a complication of dopamine agonist therapy.
Motofumi Koguchi +6 more
doaj +4 more sources
Giant prolactinoma, germline BRCA1 mutation, and depression: a case report [PDF]
Background Giant prolactinomas are very rare pituitary tumors that may exhibit an aggressive behavior and present with a life-threatening condition. Case presentation A 25-year-old white woman was admitted to our hospital with a headache, psychomotor ...
Rita Bettencourt-Silva +3 more
doaj +6 more sources
Giant Prolactinoma of Young Onset: A Clue to Diagnosis of MEN-1 Syndrome [PDF]
Multiple endocrine neoplasia (MEN) type 1 syndrome is an autosomal dominant disorder caused by germline mutations in MEN1 gene, characterized by tumours in endocrine and nonendocrine organs.
Chandrika Jayakanthi Subasinghe +4 more
doaj +3 more sources
A novel germline CDH23 variant as a likely cause of an ultra-giant prolactinoma [PDF]
Giant prolactinomas are defined as pituitary adenomas (PAs) ≥ 4 cm with plasma prolactin level > 1000 ng/ml with no other co-secretory component. The reasons for development of giant prolactinomas are not clear but genetics play an important pathogenic ...
Avaniyapuram Kannan Murugan +2 more
exaly +3 more sources

